Interferon includes both regular interferon and long-acting interferon, with regular interferon applied once every other day and long-acting interferon applied once a week for 48 weeks, or longer depending on the effectiveness of the treatment. Regular interferon is effective in treating patients with chronic hepatitis B. Long-acting interferon can obtain higher E antigen serological conversion rates, hepatitis B virus DNA and biochemical response rates compared to regular interferon. If the quantification of hepatitis B surface antigen is still greater than 20,000 U/mL after 24 weeks of interferon therapy, it is recommended to stop interferon therapy and to switch to nucleoside or nucleotide analogue antiviral therapy. During the application of interferon therapy, attention should be paid to monitoring the adverse effects of interferon.